- Company
- LG Chem Life Science achieves new quarterly sales record
- by Kim, Jin-Gu Aug 25, 2022 05:52am
- LG Chem’s Life Science company, which is in charge of the company’s pharmaceutical business, has broken its quarterly sales record in the second quarter of this year. Its flagship products - the Zemiglo series and growth hormone - had shown strong sales performance in Korea and abroad, rising nearly 20% in one year. According to the
- Company
- Celltrion Applies to Europe for IND to designate Yuflyma
- by Aug 24, 2022 05:55am
- Celltrion announced on the 23rd that it has applied to European regulators for IND to designate Humira biosimilar Yuflyma (CT-17) as an interchangeable similar. If it is designated as an interchangeable similar, it can be prescribed by replacing the original at a pharmacy without intervention by MD. Celltrion recently submitted IND to the
- Company
- Omega-3 prescription market doubles in 3 Years
- by Kim, Jin-Gu Aug 23, 2022 06:03am
- It is expected that generic companies will join and fierce competition is expected. The market for Omega-3 is rapidly expanding. The performance of outpatient prescriptions in the first half of the year has more than doubled in three years. The prescription performance of Omega-3 and Statins has increased significantly. It is predicted that c
- Company
- Abilify 1mg can be prescribed at tertiary hospitals
- by Eo, Yun-Ho Aug 22, 2022 05:53am
- A new 1mg strength formulation of ‘Abilify’ can now be prescribed at general hospitals According to industry sources, Korea Otsuka Pharmaceutical's antipsychotic ‘Abilify (aripiprazole)’ has passed the drug committees (DCs) of major hospitals in Korea, including the Seoul National University Hospital, Seoul Asan Medical Center, and Si
- Company
- Strong performance of overseas subsidiaries of companies
- by Kim, Jin-Gu Aug 22, 2022 05:52am
- Daewoong Pharmaceutical's Southeast Asian subsidiary doubled in a year. Major overseas subsidiaries of pharmaceutical bio companies showed strong sales in the first half of last year. Most of the local subsidiaries in China and Southeast Asia showed an increase in sales compared to the same period last year. Beijing Hanmi, Celltrion AP (Asia-
- Company
- Avastin biosimilar Vegzelma has obtained a European license
- by Kim, Jin-Gu Aug 22, 2022 05:52am
- Celltrion announced on the 19th that Vegzelma (CT-P16) developed with Avastin biosimilar has obtained a sales license from EC on the 18th (local time). According to Celltrion, Vegzelma received an EMA approval recommendation in June. Within two months after that, it received permission to sell full labels approved by Avastin, including metast
- Company
- Ibrance safety is OK even in male breast cancer patients
- by Eo, Yun-Ho Aug 19, 2022 05:53am
- Breast cancer treatment Ibrance has added safety-related product information in male patients. The Ministry of Food and Drug Safety recently added a phrase that male patients also showed consistent safety profiles with women in post-marketing experience through updating the permits of CDK4/6 inhibitor Ibrance of Pfizer Korea. The measure was
- Company
- US FDA approves Samsung Bioepis' high conc Humira biosimilar
- by Kim, Jin-Gu Aug 19, 2022 05:53am
- On the 18th, Samsung Bioepis announced that the U.S. Food and Drug Administration (FDA) approved the high-concentration formulation of its Humira biosimilar, ‘Hadlima 100mg/mL’ on the 15th (local time). The company plans to market the high-concentration Hadlima in the US market in July next year through its US marketing partner, Organon.
- Company
- Indication of Norvatis Beovu's DME was expanded
- by Aug 19, 2022 05:52am
- Novartis Korea announced on the 17th that Beovu, an Age-related macular degeneration treatment, has added diabetic macular edema (DME). Beovu is a treatment that inhibits neonatal vascular expression and retinal effusion leakage in combination with VEGF-A. The Beovu dose for DME treatment is administered once every 6 weeks, 6 mg (0.05 mL) for
- Company
- Why is the exp. date of the Sanofi flu vaccine short?
- by Aug 18, 2022 01:06pm
- With domestic and foreign pharmaceutical companies starting to distribute flu (influenza) vaccines, the expiration date of the Sanofi vaccine is about three months shorter than that of other products. This means that the Sanofi vaccine must be discarded in April, when Korea is still considered to be a flu epidemic period, so it cannot be used
